Amgen Inc. (NASDAQ:AMGN) Shares Sold by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. decreased its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 16.7% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,808 shares of the medical research company's stock after selling 1,769 shares during the quarter. Hennion & Walsh Asset Management Inc.'s holdings in Amgen were worth $2,744,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Centricity Wealth Management LLC purchased a new position in Amgen in the 4th quarter valued at about $25,000. Pinney & Scofield Inc. acquired a new position in shares of Amgen during the fourth quarter valued at approximately $26,000. Ritter Daniher Financial Advisory LLC DE lifted its position in shares of Amgen by 66.2% in the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after acquiring an additional 51 shares in the last quarter. Synergy Investment Management LLC acquired a new stake in shares of Amgen in the fourth quarter worth approximately $34,000. Finally, Atala Financial Inc purchased a new stake in shares of Amgen during the fourth quarter worth approximately $34,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on AMGN. Bank of America raised their price objective on Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a report on Wednesday, March 5th. Royal Bank of Canada decreased their price target on shares of Amgen from $324.00 to $320.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. Mizuho boosted their price target on shares of Amgen from $235.00 to $280.00 and gave the stock a "neutral" rating in a research report on Wednesday, May 7th. Johnson Rice set a $294.00 price objective on shares of Amgen in a report on Wednesday, March 5th. Finally, Piper Sandler decreased their target price on shares of Amgen from $329.00 to $328.00 and set an "overweight" rating on the stock in a research note on Friday, May 16th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $309.22.

Amgen Trading Up 0.0%

Shares of AMGN traded up $0.09 during trading on Thursday, reaching $287.10. 2,521,343 shares of the company traded hands, compared to its average volume of 2,809,728. The stock has a 50-day simple moving average of $282.39 and a 200-day simple moving average of $285.31. The stock has a market cap of $154.38 billion, a PE ratio of 38.03, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating the consensus estimate of $4.18 by $0.72. The company had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Amgen's revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the company posted $3.96 EPS. On average, analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.